New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins

Area of Science:

• Immunology
• Cell Biology
• Regenerative Medicine

Background:

• Mesenchymal stromal cells (MSCs) possess potent immunosuppressive properties.
• Known immunosuppressive mechanisms include indoleamine 2,3-dioxygenase (IDO) and factors like IL-10, TGF-β, and PGE2.
• The completeness of these known mechanisms in MSC-mediated immunosuppression remains unclear.

Purpose of the Study:

• To investigate novel mechanisms underlying MSC immunosuppression.
• To identify additional factors beyond IDO, IL-10, TGF-β, and PGE2 that contribute to MSC immunosuppressive function.
• To elucidate the role of galectins in MSC-mediated immune regulation.

Main Methods:

• Utilized small interfering RNAs (siRNAs) to inhibit galectin-1 and galectin-3 gene expression in human bone marrow MSCs.
• Assessed the impact of galectin inhibition on MSCs' ability to suppress allogeneic T cell proliferation in mixed lymphocyte reactions.
• Quantified the expression and secretion of galectin-1 and galectin-3 by MSCs.

Main Results:

• Galectin-1 and galectin-3 are constitutively expressed and secreted by human bone marrow MSCs.
• Inhibition of galectin-1 and galectin-3 gene expression abrogated the immunosuppressive effect of MSCs on allogeneic T cells.
• These findings indicate galectins are key regulators of MSC immunosuppressive function.

Conclusions:

• Galectins, specifically galectin-1 and galectin-3, play a critical role in the immunosuppressive capacity of MSCs.
• These galectins represent novel targets for modulating MSC function.
• A deeper understanding of MSC immunosuppressive mechanisms, including galectins, can advance therapeutic applications, such as treating graft-versus-host disease.